Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile InfectionGlobeNewsWire • 12/20/21
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021GlobeNewsWire • 11/15/21
Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte GaykoGlobeNewsWire • 11/03/21
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of DirectorsGlobeNewsWire • 10/08/21
(SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? Contact Johnson Fistel Regarding InvestigationPRNewsWire • 10/02/21
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021GlobeNewsWire • 09/30/21
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021PRNewsWire • 09/30/21
FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection TrialsBenzinga • 09/22/21
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021GlobeNewsWire • 08/11/21
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug RidinilazoleGlobeNewsWire • 07/12/21
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePosterGlobeNewsWire • 07/01/21
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?Zacks Investment Research • 05/19/21
Summit Therapeutics Unveils Preclinical Candidate For Multidrug-Resistant InfectionsBenzinga • 05/18/21
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021GlobeNewsWire • 05/17/21
Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights OfferingGlobeNewsWire • 05/05/21